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Large-scale genome-wide association studies (GWAS) in mainly white Europeans have identified at least 50 genetic loci to be robustly associated with obesity-related traits \[[@CR1]--[@CR12]\]. A cluster of common variants in the first intron of the fat mass and obesity-associated gene (*FTO*) was the first obesity-susceptibility locus to be identified by two independent GWAS in 2007 \[[@CR1], [@CR2]\] and has since been consistently replicated by many others and for a variety of obesity-related traits \[[@CR7], [@CR9], [@CR13]--[@CR15]\]. Of all currently identified obesity-susceptibility loci, the *FTO* locus has the most pronounced effect on BMI and obesity risk, at least in individuals of European descent. Each minor allele of any commonly investigated variant in *FTO* increases BMI by 0.30--0.40 kg/m^2^ (equivalent to 870--1,150 g for a person 1.7 m tall) and risk of obesity by ∼20% \[[@CR7], [@CR15]\]. The minor allele of the *FTO* variant is common (minor allele frequency (MAF)=∼42%) in white Europeans, such that 66% of Europeans carry at least one risk allele and 18% carry two risk alleles. Because of the high prevalence of the risk allele and its relatively strong effect on BMI, the *FTO* locus explains most (0.34%), yet little, of the variation in BMI in Europeans \[[@CR7]\].

*FTO* has also been examined as an obesity-susceptibility locus in populations of non-white European origin. While the initial replication efforts in East Asian populations were inconsistent \[[@CR16], [@CR17]\], a growing number of studies have provided evidence that genetic variation in *FTO* influences BMI and obesity risk also in Chinese, Japanese, Korean and Filipino populations \[[@CR18]--[@CR27]\]. A GWAS for BMI in 7,861 Koreans identified variation in *FTO* (rs9939609) as the most significantly associated locus, nearly reaching genome-wide significance (*p* = 1.5 × 10^−7^) \[[@CR28]\]. Furthermore, literature-based meta-analyses in Asians reported that the minor allele for the rs9939609 *FTO* single-nucleotide polymorphism (SNP) significantly (*p* = 9 × 10^−9^) increased the risk of obesity, but no other obesity-related traits were examined \[[@CR18], [@CR29], [@CR30]\]. Fewer studies in South Asians have been reported, two of which confirmed the association between the *FTO* locus and obesity susceptibility \[[@CR31], [@CR32]\], whereas one did not \[[@CR33]\]. The prevalence of the risk allele in East Asians (∼20%) and South Asians (∼30%) is substantially lower than in Europeans, and the reported effect sizes in both East and South Asians vary widely for BMI (OR 0.13--0.83 kg/m^2^ per minor allele) and obesity risk (OR 1.02--1.48 per minor allele) \[[@CR16], [@CR18], [@CR20]--[@CR25], [@CR27], [@CR34]--[@CR39]\].

*FTO* was first identified as a type 2 diabetes-susceptibility gene, but, as further adjustment for BMI abolished the association with type 2 diabetes \[[@CR1]\], it was suggested that *FTO* is primarily an obesity-susceptibility locus. However, the BMI-independent role of *FTO* in type 2 diabetes remains a matter of debate, particularly in Asians but also in white Europeans. While several studies have reported that the association between the *FTO* locus and risk of type 2 diabetes remained significant after adjustment for BMI \[[@CR15], [@CR18], [@CR33], [@CR35], [@CR40], [@CR41]\], others could not confirm this \[[@CR21], [@CR30], [@CR32], [@CR37], [@CR42]\].

To firmly establish the association between the *FTO* locus and obesity susceptibility in East and South Asians and to assess its effect size and potential heterogeneity across Asian populations, we performed a systematic meta-analysis of data from 32 populations, including 96,551 men and women, using standardised study-specific association analyses. Furthermore, we examined whether the *FTO* locus is associated with type 2 diabetes independently of its association with BMI.

Methods {#Sec2}
=======

**Literature search and study identification** We designed a meta-analysis based on de novo analyses of data according to a standardised plan to achieve the greatest consistency possible across studies. We identified all published studies (before September 2010) that had examined the association of genetic variation in *FTO* with risk of obesity and type 2 diabetes and with obesity-related continuous traits in East and South Asian adults (age ≥18 years) by a PubMed literature search using the key words 'FTO', 'fat mass and obesity associated gene' and 'genome-wide association study'. References from the identified papers were subsequently screened to identify additional studies and to ensure that the list of eligible studies was complete. The literature search was carried out by two investigators independently, who cross-checked their search results for completeness.Our literature search identified 38 publications, one of which was excluded because it was a subsample of another identified study. We invited the corresponding authors of the remaining 37 publications to join our meta-analysis, of which 26 agreed to participate and eventually 22 submitted raw data or summary statistics. We also included a Korean population with previously unpublished data (Y. M. Kim, J. Shin, C.B. Lee, M.K. Kim, Y. Tabara, T. Miki and B.Y. Choi), which was presented by a contributing author.Taken together, our meta-analysis included data for 31 populations from 22 publications and one unpublished study, with 96,551 individuals altogether. The study identification and selection process is illustrated in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Study identification and inclusion in the meta-analysesAll studies were conducted according to the Declaration of Helsinki. Informed consent was obtained from all participants, and the studies were approved by the ethics committees of the participating institutions.

**Genotyping** The rs9939609 *FTO* SNP was examined in 18 studies, whereas proxy SNPs were used in 14 studies. More specifically, the rs8050135 SNP was genotyped in 11 studies of East Asians and one of South Asians, and the rs3751812 and rs17817449 SNP were each genotyped once in studies of East Asians (electronic supplementary material \[ESM\] Table [1](#MOESM9){ref-type="media"}). The linkage disequilibrium between rs9939609 and the three proxies (rs8050135, 3751812, rs17817449) is perfect (*r*^2^ = 1) in populations of East Asian origin, based on CHB+JPT data from the HapMap (Rel 24/Phase II). The linkage disequilibrium between rs9939609 and rs8050135 in Indian Asians is very high (*r*^2^ \> 0.98), based on a subsample (*n* = 305) of the participating Lolipop study.The genotyping success rate and concordance rate were \>95%, and genotype distributions were in Hardy--Weinberg equilibrium (*p* \> 0.01) in all participating studies (ESM Table [1](#MOESM9){ref-type="media"}).

**Statistical analysis** As case--control definitions and statistical analyses used in the published papers were inconsistent, we asked analysts of each of the participating cohorts to re-analyse their data according to a standardised analysis plan. Summary statistics of each study were subsequently meta-analysed.

**Obesity-susceptibility traits and type 2 diabetes** Overweight was defined as a BMI ≥24 kg/m^2^, and obesity as a BMI ≥28 kg/m^2^ according to the definition proposed by the Working Group on Obesity in China \[[@CR43]\]. Anthropometric data, including weight, height, waist circumference, hip circumference and body fat percentage, were collected in each study as described previously (ESM Table [1](#MOESM9){ref-type="media"}), BMI was calculated as weight (kg) divided by height squared (m^2^), and WHR as waist circumference (cm) divided by hip circumference (cm). Raw data were used for analyses.Type 2 diabetes was defined as meeting one or more of the following criteria: (1) fasting glucose ≥7.0 mmol/l; (2) 2-h glucose ≥11.1 mmol/l; (3) previous diagnosis of type 2 diabetes; (4) HbA~1c~ ≥6.5% (48 mmol/mol); (5) self-reported type 2 diabetes (ESM Table [1](#MOESM9){ref-type="media"}).

**Study-specific de novo data analyses** Association analyses within each study were performed for the total population and for men and women separately using additive and dominant genetic models. The associations of *FTO*-rs9939609 (or proxy) with risk of obesity and type 2 diabetes were assessed with multiple logistic regression models. Generalised linear models were used to assess the associations of *FTO*-rs9939609 (or proxy) with obesity-related continuous traits. In studies with a case--control design, analyses for continuous traits were conducted in control samples only. All analyses were adjusted for age and sex (sex-stratified analyses were only adjusted for age). The association with type 2 diabetes was also analysed with adjustment for BMI. Adjustments were performed by including the covariates (age, sex and/or BMI) as a linear term in the association model.Summary statistics from the study-specific association analyses were reported in a standardised Excel form by the analysts of each study and collected centrally for meta-analyses.

**Meta-analyses** Data extraction from the forms and meta-analyses was performed independently by two investigators and cross-checked for consistency. All ambiguities were clarified with the respective analysts before the final meta-analyses.ORs and beta coefficients from the individual studies were pooled using DerSimonian and Laird random-effects meta-analyses \[[@CR44]\]. Meta-analyses were performed of all studies combined. Because of differences in genetic background as well as in susceptibility to obesity and type 2 diabetes, meta-analyses were also stratified by East Asian and South Asian origin of the populations. Furthermore, East Asians were further stratified according to their country of origin.Between-study heterogeneity was tested by Cochrane's Q test and quantified by the *I*^2^ index. *I*^2^ values of \<25%, 25--75% and \>75% were defined as low, moderate and high heterogeneity, respectively \[[@CR45]\]. To examine the sources of heterogeneity in our meta-analyses, we performed random-effects meta-regressions, where the between-study variance was estimated with the restricted maximum likelihood approach. Meta-regressions included the following study-specific variables as covariates: year of publication, country of origin, sample size, study design, mean age and mean BMI.A funnel plot, along with Begg's and Egger's tests, was used to test for the presence of publication bias.Statistical analyses were performed with the Stata 9.0 software (StataCorp LP, College Station, TX, USA). Meta-analyses and meta-regressions were implemented by the *metan* and *metareg* commands of Stata, respectively. *p* \< 0.05 was considered to be significant, except for Cochrane's Q test for heterogeneity and Begg's and Egger's tests for publication bias, where a level of *p* \< 0.10 was used.The variation in obesity-related continuous traits explained by the *FTO* variant was evaluated using the equation 2*f*(1−*f*)*a*^2^, where *f* is the frequency of the variant and *a* is its additive standardised effect \[[@CR5]\]. Population-attributable risk (PAR) was calculated as $\documentclass[12pt]{minimal}
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**Characteristics of populations included in the meta-analyses** Analyses were conducted in Chinese Hans (China Mainland: *n* = 10; Singapore: *n* = 2), Japanese (*n* = 7), Indians (*n* = 7), Koreans (*n* = 4), Singapore Malays (*n* = 1) and Filipinos (*n* = 1; Table [1](#Tab1){ref-type="table"}). Fifteen of the populations were case--control designed for obesity (*n* = 3) or type 2 diabetes (*n* = 8) or both (*n* = 4), whereas 17 populations were population-based. The mean age and BMI of the populations ranged from 27.9 to 66.8 years and from 20.5 to 27.1 kg/m^2^, respectively. The prevalence in population-based studies ranged from 3.1% to 37.9% for obesity and from 2.9% to 41.9% for type 2 diabetes.Table 1Descriptive information of studies included in the meta-analyses, sorted by ethnicity, study design and publication yearPaperStudyPublication yearEthnicityCountryStudy designSample sizeMean age (years)Mean BMI (kg/m^2^)*FTO* SNPMAFObeseOWNWT2DMNFGQT analysesLi et al. \[[@CR16]\]NHAPC2008East AsianChinaPopulation based4721,2151,5034231,8933,19058.6224.43rs99396090.11Sha et al. \[[@CR55]\]GSBC2009East AsianChinaPopulation based783261,223n.a.n.a.1,62734.4922.21rs99396090.12Hu et al. \[[@CR56]\]SHDS2009East AsianChinaCase--control^b^n.a.n.a.n.a.1,7591,7911,79157.3323.57rs80501360.12Li et al. \[[@CR35]\]WDS2010East AsianChinaCase--control^a,\ b^2439761,3688771,4051,40544.2321.45rs99396090.12Cheung et al. \[[@CR24]\]CRISPS2010East AsianChinaCase--control^a^419n.a.691n.a.n.a.69144.9821.19rs80501360.12Liu et al. \[[@CR18]\]n.a.2010East AsianChinaCase--control^a,\ b^2777948931,7671,9611,96158.0924.52rs99396090.12Ng et al. \[[@CR21]\]CUHK2010East AsianChinaCase--control^b,\ c^1,1472,2932,4325,87258358341.3122.87rs37518120.12Shu et al. \[[@CR42]\]SGWAS2010East AsianChinaCase--control^b^n.a.n.a.n.a.1,0432,1702,17049.2423.30rs99396090.12Wen et al. \[[@CR57]\]FLSGS2010East AsianChinaCase--control^b^n.a.n.a.n.a.1,1601,1271,12759.0924.13rs80501360.12Chang et al. \[[@CR23]\]NTUH2008East AsianTaiwanCase--control^a,\ b^7376777198811,2541,25461.1921.60rs99396090.14Cha et al. \[[@CR25]\]Kirin2008East AsianKoreaPopulation based252304361n.a.n.a.91727.9126.39rs178174490.14Cha et al. \[[@CR58]\]KCMS2009East AsianKoreaPopulation based61261688n.a.n.a.1,01043.1422.77rs80501360.12Kim et al. (unpublished data)YangPyeung Cardiovascular Cohort StudyEast AsianKoreaPopulation based3399951,0921942,0612,42657.6024.49rs99396090.12Ng et al. \[[@CR34]\]Korea SNUH2008East AsianKoreaCase--control^b^n.a.n.a.n.a.75862962964.7023.52rs80501360.12Takeuchi et al. \[[@CR59]\]CAGE-Amagasaki2009East AsianJapanPopulation based3881,5623,719n.a.n.a.5,66048.8622.99rs99396090.19Takeuchi et al. \[[@CR59]\]CAGE-Fukuoka2009East AsianJapanPopulation based7213,7638,076n.a.n.a.12,56062.5923.05rs99396090.19Takeuchi et al. \[[@CR59]\]CAGE-BMI2009East AsianJapanPopulation based1686071,006n.a.n.a.1,78166.8223.69rs99396090.20Karasawa et al. \[[@CR19]\]Takahata2010East AsianJapanPopulation based2208861,5332152,3062,63963.0423.48rs99396090.20Hotta et al. \[[@CR20]\]GWASJPN obesity2008East AsianJapanCase--control^a^1,559n.a.1,541n.a.n.a.1,54147.5221.21rs99396090.18Omori et al. \[[@CR37]\]RIKEN T2D2008East AsianJapanCase--control^b^n.a.n.a.n.a.4,5842,2622,26244.8422.86rs80501360.20Takeuchi et al. \[[@CR59]\]CAGE-T2DM2009East AsianJapanCase--control^b^n.a.n.a.n.a.6,7817,307n.a.64.3523.47rs99396090.19Marvelle et al. \[[@CR27]\]CLHNS2008East AsianPhilippinesPopulation based3215608361551,4631,71748.5124.31rs99396090.18Tan et al. \[[@CR22]\]SP22008East AsianSingapore (Chinese)Population based1956241,6091452,2482,43048.1122.88rs80501360.12Tan et al. \[[@CR22]\]SiMES2008East AsianSingapore (Malays)Population based8488268467871,2482,52059.0426.38rs80501360.30Tan et al. \[[@CR22]\]SDCS2008East AsianSingapore (Chinese)Case--control^c^426809757n.a.n.a.n.a.64.2725.34rs80501360.14Chambers et al. \[[@CR6]\]LOLIPOP (IA317)2008South AsianIndiaPopulation based7278585364341,6512,24748.2226.83rs80501360.33Chambers et al. \[[@CR6]\]LOLIPOP (IA610)2008South AsianIndiaPopulation based2,4792,6471,4231,7804,7157,06055.3827.14rs80501360.32Tan et al. \[[@CR22]\]SINDI2008South AsianIndiaPopulation based7609108589741,3482,52858.0126.20rs80501360.33Yajnik et al. \[[@CR33]\]Parthenon2009South AsianIndiaPopulation based136320511n.a.n.a.96732.4423.76rs99396090.33Yajnik et al. \[[@CR33]\]PMNS2009South AsianIndiaPopulation based592711,546501,6811,87632.7120.83rs99396090.31Sanghera et al. \[[@CR40]\]Sikh Diabetes Study2008South AsianIndiaCase--control^b^n.a.n.a.n.a.1,13876576550.8526.25rs99396090.31Yajnik et al. \[[@CR33]\]WELLGEN2009South AsianIndiaCase--control^b^n.a.n.a.n.a.1,9671,6811,68132.3920.50rs99396090.31Individuals from CAGE-T2DM study were selected from other three CAGE population-based studies^a^Obese case--control study^b^T2DM case--control study^c^Obese case--control study conducted in T2DM casesn.a., data not available or not used in meta-analysis; NFG, normal fasting glucose; NW, normal weight; OW, overweight; QT, quantitative trait; T2DM, type 2 diabetesThe MAF of *FTO*-rs9939609 (or proxy) is 12--14% in Chinese Hans and Koreans, 18--20% in Japanese and Filipinos, and 30--33% in Singapore Malays and Indians (Table 1).

**Associations with obesity and overweight** A total of 24 populations (*n*~obese~ = 13,032; *n*~overweight~ = 22,474; *n*~normalweight~ = 35,767) were available for meta-analyses of the association between the *FTO* variant and risk of obesity and overweight.Each additional *FTO*-rs9939609 minor (A) allele increased the odds of obesity by 1.25 (*p* = 9.0 × 10^−19^) compared with normal weight individuals (Fig. [2](#Fig2){ref-type="fig"}), and by 1.17 (*p* = 7.4 × 10^−11^) compared with non-obese individuals (ESM Fig. [1](#MOESM2){ref-type="media"}). Each additional minor allele increased the odds of overweight by 1.13 (*p* = 1.0 × 10^−11^; ESM Fig. [2](#MOESM3){ref-type="media"}). The odds of obesity and overweight were the same in both East Asian and South Asian populations (*p* = 0.18 and 0.84, respectively; ESM Table [2](#MOESM10){ref-type="media"}). Associations were similar in men and women (ESM Table [3](#MOESM11){ref-type="media"}). The heterogeneity across all studies was low (13% ≤ *I*^2^ ≤ 19%).Fig. 2Association of *FTO*-rs9939609 (or proxy) with obesity. Study-specific association analyses assumed an additive genetic model, comparing obese with normal-weight individuals, adjusted for age and sex. Effect sizes were combined using random-effects meta-analyses (DerSimonian--Laird method)When a dominant genetic model was used, the odds were only slightly higher than for the additive genetic model (ESM Table [4](#MOESM12){ref-type="media"}).

**Association with type 2 diabetes** In our meta-analysis of 22 populations (*n*~cases~ = 33,744, *n*~controls~ = 43,549), each additional *FTO*-rs9939609 minor allele increased the odds of type 2 diabetes by 1.15 (*p* = 5.5 × 10^−8^) when adjusted for age and sex (Fig. [3](#Fig3){ref-type="fig"}). Further adjustment for BMI attenuated, but did not abolish, the association with type 2 diabetes (OR 1.10, *p* = 6.6 × 10^−5^) (Fig. [4](#Fig4){ref-type="fig"}). Results were similar in East Asians and South Asians (ESM Table [2](#MOESM10){ref-type="media"}), in men and women (ESM Table [3](#MOESM11){ref-type="media"}), and when a dominant model was used (ESM Table [4](#MOESM12){ref-type="media"}).Fig. 3Association of *FTO*-rs9939609 (or proxy) with type 2 diabetes. Study-specific association analyses assumed an additive genetic model adjusted for age and sex. Effect sizes were combined using random-effects meta-analyses (DerSimonian--Laird method)Fig. 4Association of *FTO*-rs9939609 (or proxy) with type 2 diabetes adjusted for BMI. Study-specific association analyses assumed an additive genetic model adjusted for age, sex, and BMI. Effect sizes were combined using random-effects meta-analyses (DerSimonian--Laird method)The association results across all studies showed moderate heterogeneity (44% ≤ *I*^2^ ≤ 48%; Figs [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). Meta-regression analyses revealed that the difference in study design contributed to some of the heterogeneity. Subsequent subgroup analyses showed that the association with type 2 diabetes was more pronounced in studies with a case--control design (OR \[95% CI\] = 1.19 \[1.14, 1.23\], *p* = 3.7 × 10^−19^, *I*^2^ = 0.0%) than in cohort studies (OR \[95% CI\] = 1.09 \[0.99, 1.20\], *p* = 0.07, *I*^2^ = 54.4%), which showed moderate heterogeneity (ESM Table [5](#MOESM13){ref-type="media"}).

**Associations with obesity-related continuous traits** The meta-analyses of the association of *FTO*-rs9939609 with BMI, waist circumference, hip circumference, WHR and body fat percentage included 30 (*n* = 71,022), 22 (*n* = 51,543), 20 (*n* = 48,508), 20 (*n* = 48,508) and nine (*n* = 19,580) populations, respectively.Each additional *FTO*-rs9939609 minor allele was associated with a 0.26 kg/m^2^ higher BMI (*p* = 2.8 × 10^−17^; equivalent to ∼750 g/allele for a person 1.7 m tall) (Fig. [5](#Fig5){ref-type="fig"}), 0.51 cm larger waist circumference (*p* = 3.0 × 10^−9^) (ESM Fig. [3](#MOESM4){ref-type="media"}), 0.36 cm larger hip circumference (*p* = 0.0003) (ESM Fig. [4](#MOESM5){ref-type="media"}), 0.003 greater WHR (*p* = 1.2 × 10^−6^; ESM Fig. [5](#MOESM6){ref-type="media"}), and 0.31% higher body fat percentage (*p* = 0.0005) (ESM Fig. [6](#MOESM7){ref-type="media"}). All associations were very similar between East and South Asians (ESM Table [2](#MOESM10){ref-type="media"}), between men and women (ESM Table [3](#MOESM11){ref-type="media"}), or when a dominant genetic model was used (ESM Table [4](#MOESM12){ref-type="media"}).Fig. 5Association of *FTO*-rs9939609 (or proxy) with BMI. Study-specific association analyses assumed an additive genetic model adjusted for age and sex. Effect sizes were combined using random-effect meta-analyses (DerSimonian--Laird method)We observed moderate heterogeneity across studies in the associations with BMI and hip circumference (BMI: *I*^2^ = 33%; hip circumference: *I*^2^ = 51%; Fig. [5](#Fig5){ref-type="fig"}; ESM Fig. [4](#MOESM5){ref-type="media"}). Meta-regression suggested that, for BMI, the heterogeneity was mainly due to difference in mean age and mean BMI among different populations. For hip circumference, the heterogeneity was mainly attributed to difference in mean BMI, i.e. the effect of the *FTO* minor allele tended to be larger in populations with a mean BMI ≥24 kg/m^2^, compared with those with a mean BMI \<24 kg/m^2^.*FTO*-rs9939609 explained 0.16% and 0.20% of the inter-individual variation in BMI in East and South Asian populations, respectively. The proportion of variation in other obesity-related continuous traits explained by *FTO*-rs9939609 was \<0.10% (ESM Table [2](#MOESM10){ref-type="media"}).

**Publication bias** The funnel plots for the associations with obesity, type 2 diabetes, waist circumference, WHR and body fat percentage were symmetrical and the results for Begg's and Egger's tests were non-significant (*p* ≥ 0.10), indicating that our results were not affected by publication bias (ESM Fig. [7](#MOESM8){ref-type="media"}). However, there was some evidence of publication bias and/or genetic heterogeneity for BMI (Begg's test, *p* = 0.08; Egger's test, *p* = 0.07) and hip circumference (Begg's test, *p* = 0.03; Egger's test, *p* = 0.08; ESM Fig. [7](#MOESM8){ref-type="media"}).

Discussion {#Sec4}
==========

This meta-analysis, combining data of 96,551 Asians from 32 populations, further confirms that genetic variation in *FTO* is associated with increased risk of obesity in East and South Asians. Despite differences in genetic background and obesity susceptibility between East and South Asians, the effect of *FTO* on obesity and related traits was generally similar to, or only somewhat smaller than, those reported for white Europeans. We furthermore confirm that variation in *FTO* is associated with increased risk of type 2 diabetes, an association that, unlike in white Europeans, is not abolished after adjustment for BMI in both East and South Asians.

Large-scale studies in individuals of white European descent have reported that each additional *FTO* minor allele increases the odds of obesity by 1.20--1.32-fold \[[@CR1], [@CR5], [@CR7], [@CR47]\]. The association with obesity observed in Asians in the present study was remarkably similar, with each additional minor allele increasing obesity risk by 1.25-fold (95% CI 1.19, 1.31), consistent with the association observed for obesity in previous literature-based meta-analyses of case--control studies in East and South Asians \[[@CR18], [@CR29], [@CR30]\].

The association of the *FTO* variant with overweight was the same in East and South Asians (OR 1.13 per minor allele) and very similar to the effects (ORs ranging from 1.13 to 1.18) that have been reported in large-scale studies of white Europeans \[[@CR1], [@CR7], [@CR47]\]. While the effect sizes observed for the influence of *FTO* on obesity and overweight in Asians are very similar to those of Europeans, it should be noted that the definitions of obesity and overweight are different, as BMI cut-offs are somewhat lower in Asians than in Europeans, consistent with the association of BMI with metabolic disease \[[@CR48]\].

The *FTO* minor allele increases BMI by 0.26 kg/m^2^ (equivalent to ∼750 g/allele for a person 1.7 m tall) in Asians, with very similar results for East and South Asians. This observation suggests that the effect of *FTO* on BMI in Asians is substantially smaller than the effect observed in a meta-analysis of more than 125,000 white Europeans (0.39 kg/m^2^ per minor allele, or 1,130 g per minor allele) \[[@CR7]\]. This difference may be due to the fact that BMI in Asians does not represent exactly the same adiposity phenotype as in Europeans. However, given that other large-scale studies in white Europeans have reported effects for *FTO* on BMI that range between 0.26 and 0.39 kg/m^2^, the comparison between Asians and Europeans should be made with caution \[[@CR1], [@CR3], [@CR5], [@CR15], [@CR47]\]. The *FTO* variant also showed convincing association with measures of fat distribution such as waist and hip circumference and WHR in Asians. Despite the often described difference in abdominal obesity between East and South Asians, the effect sizes were very similar in the two groups. Consistent with the observations for BMI, the effect sizes tended to be somewhat smaller than those reported for white Europeans. For example, each additional *FTO* minor allele increased waist circumference by 0.51 cm in Asians, whereas large-scale studies in Europeans have reported an increase of 0.73--1.00 cm \[[@CR1], [@CR9], [@CR47]\].

As the MAF of the *FTO* variant is substantially lower in Asians (East Asians, ∼17%; South Asians, ∼32%) than in white Europeans (∼45%), and as the effect of this allele on obesity-related traits is similar or somewhat lower in Asians than in white Europeans, the overall contribution of genetic variation in *FTO* to obesity susceptibility will be lower in Asians, in particular East Asians. For example, the *FTO* variant explained less of the inter-individual variation in BMI in Asians (East Asians, 0.16%; South Asians, 0.20%) than in white Europeans (0.34%) \[[@CR7]\]. Furthermore, the low risk allele frequency led to a lower PAR for the risk of obesity (East Asians, 8.3%; South Asians, 10.6%) and overweight (East Asians, 4.1%; South Asians, 7.8%) in Asians than in white Europeans (obesity, 20.4%; overweight, 12.7%) \[[@CR1]\].

The *FTO* locus was first identified in a GWAS for type 2 diabetes in white Europeans, i.e. each minor allele increased the odds of diabetes by 1.15-fold \[[@CR1]\]. However, after adjustment for BMI, the association between the *FTO* variant and type 2 diabetes was completely abolished (OR 1.03), suggesting that *FTO* is primarily an obesity-susceptibility locus \[[@CR1]\]. In our meta-analysis, we observed a similar effect of *FTO* on risk of type 2 diabetes, with each minor allele increasing the odds by 1.15-fold. Interestingly, adjustment for BMI did not abolish the association, but only slightly attenuated it to a 1.10-fold increased risk of type 2 diabetes for each additional minor allele. These observations were similar in East and South Asians, suggesting that the *FTO* locus influences the risk of type 2 diabetes, at least in part, independently of its effect on BMI. The reason for the discrepancy between the original observations in Europeans and our observations in Asians are not known, but may be due to the fact that *FTO* seems to have a smaller effect on BMI in Asians than in Europeans. It may also be due to the fact that BMI, as suggested above, represents a different adiposity phenotype in Asians than in Europeans because of differences in body composition. Although BMI is a marker for general adiposity, it does not distinguish between fat mass and fat-free mass and does not reflect regional fat distribution. Observational studies have suggested that, for a given amount of total body fat, East and South Asians have more abdominal fat and less muscle mass than white Europeans \[[@CR49], [@CR50]\]. However, while it has been generally believed that in white Europeans the association with type 2 diabetes is fully mediated by the effect of *FTO* on BMI, not all studies confirm this observation. A recent large-scale study in 41,504 Scandinavians found that the *FTO* minor allele indeed increased type 2 diabetes risk (OR 1.13), but this association remained present (OR 1.09) after adjustment for BMI, consistent with the observations in the present study. The biological pathways that underlie the independent association between *FTO* variation with obesity and type 2 diabetes remain unclear. However, results of gene expression studies have shown that *FTO* expression in human islets cells is not associated with BMI \[[@CR51]\], whereas *FTO* mRNA and protein levels in muscle are increased in individuals with type 2 diabetes compared with non-diabetic obese individuals or healthy lean controls \[[@CR52]\]. Furthermore, FTO overproduction in myotubes suggested a role for FTO in oxidative metabolism, lipogenesis and oxidative stress in muscle, a cluster of metabolic defects characteristic of type 2 diabetes \[[@CR52]\].

Despite the fact that our meta-analyses included Asians with different genetic backgrounds, the overall heterogeneity of the association effects was generally only low to moderate. Interestingly, we found that the associations were generally very similar in East and South Asians, although these populations are known to have genetically different origins \[[@CR53]\]. Furthermore, we found no differences between men and women, consistent with the observations in white Europeans \[[@CR7]\]. We found some evidence that age may contribute to the heterogeneity of the association between *FTO* and BMI. Life course effects have been reported in white Europeans \[[@CR54]\], and longitudinal analyses will be needed to establish this in Asian populations. Longitudinal studies are also more appropriate than cross-sectional studies for disentangling the intricate interplay between *FTO*, obesity and type 2 diabetes throughout life \[[@CR15]\].

It should be noted that the association between *FTO* variation and obesity risk in Asians had been established in three earlier meta-analyses \[[@CR18], [@CR29], [@CR30]\]. These meta-analyses were substantially smaller than the present ones and focused solely on case--control analyses of obesity and type 2 diabetes, while no continuous traits were studied. The meta-analysis by Liu et al \[[@CR18]\] included individuals of East and South Asian origin, which were analysed together without comparison of effect sizes between the two populations. This study also examined the association with type 2 diabetes, but did not explore the association after adjustment for BMI \[[@CR18]\]. Furthermore, the three previous meta-analyses were all literature-based and thus more prone to publication bias, whereas our meta-analysis was designed on the basis of a de novo analysis of data according to a standardised plan in all studies identified as having available data and agreement to participate. No evidence of publication bias was observed except for the associations with BMI and hip circumference. The analytical consistency across studies helped minimise between-study heterogeneity. Although our results are representative of individuals of Southeast Asian, East Asian and South Asian descent, the association of *FTO* with risk of obesity and type 2 diabetes in other Asian populations remains to be examined.

In summary, we have firmly established that genetic variation in the first intron of *FTO* is associated with increased risk of obesity and type 2 diabetes in Asians, with effect sizes similar to those in Europeans. Furthermore, we confirm that the association of *FTO* with risk of type 2 diabetes is partly independent of BMI.
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